Revolution Medicines, Inc. – NASDAQ:RVMD

Add to watchlist

$36.54

-7.67

-17.35%

Market closed

Open in about 13 hours

-2.06%

month

-2.06%

quarter

+50.84%

year

Market Cap	7.91B
Enterprise value	1.58B

P/E	-6.85
EV/Sales	44.83
EV/EBITDA	-6.54
Price/Sales	47.58
Price/Book	2.45
PEG ratio	0.34
EPS	-3.75

Revenue	N/A
EBITDA	-550.02M
Income	-484.27M
Revenue Q/Q	-100%
Revenue Y/Y	-86.88%

Profit margin	-702.95%
Oper. margin	-730.01%
Gross margin	0%
EBIT margin	-730.01%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Revolution Medicines Stock Forecast

M Q Y

Last Year

$63.86

Potential upside: 74.75%

Analysts Price target
Financials & Ratios estimates

Revolution Medicines, Inc. (NASDAQ:RVMD): Profit margin
Jun 2023	3.82M	-98.29M	-2570.55%
Sep 2023	0	-108.43M
Dec 2023	742K	-161.53M	-21770.49%
Mar 2024	0	-116.00M

Revolution Medicines, Inc. (NASDAQ:RVMD): Debt to assets
Jun 2023	1073709000	142.87M	13.31%
Sep 2023	984232000	146.77M	14.91%
Dec 2023	2088591000	262.39M	12.56%
Mar 2024	1908362000	182.89M	9.58%

Revolution Medicines, Inc. (NASDAQ:RVMD): Cash Flow
Jun 2023	-67.12M	-43.54M	64.63M
Sep 2023	-100.49M	77.35M	1.01M
Dec 2023	-120.56M	-380.40M	839.35M
Mar 2024	-160.56M	-247.96M	810K

Revolution Medicines alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Revolution Medicines
Employees

Revolution Medicines, Inc. (NASDAQ:RVMD): Employee count
Aug 2023	259
Sep 2023	292
Oct 2023	292
Nov 2023	292
Dec 2023	338
Jan 2024	338
Feb 2024	338
Mar 2024	378
Apr 2024	378
May 2024	378
Jun 2024	411
Jul 2024	411

Revolution Medicines
Hedge Funds Holdings Q1 2023

47.24% -52.76%

of RVMD is owned by hedge funds

84 -50

hedge funds hold RVMD stock

38.08M -50.30M

shares is hold by hedge funds

RVMD hedge funds holdings changes

Revolution Medicines
Insider Trading

Revolution Medicines, Inc. (NASDAQ:RVMD): Insider trades (number of shares)
Period	Buy	Sel
Jan 2024	0	18167
Mar 2024	0	38509
Apr 2024	0	19655
May 2024	0	11500
Jun 2024	0	55120
Jul 2024	0	56221
Aug 2024	0	26667
Sep 2024	0	41076
Oct 2024	0	132866
Nov 2024	0	95220
Dec 2024	1304347	24940

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Option	18 Dec 2024	GOLDSMITH MARK A director, officer..	Common Stock	30,846	$0.49	$15,115
Option	18 Dec 2024	GOLDSMITH MARK A director, officer..	Stock Option (Right to Buy)	30,846	$0.49	$15,115
Sale	16 Dec 2024	KELSEY STEPHEN MICHAEL officer: See Remarks officer: See Remarks	Common Stock	4,663	$45.4	$211,719
Sale	16 Dec 2024	HORN MARGARET A officer: Chief Op..	Common Stock	4,329	$45.4	$196,554
Sale	16 Dec 2024	GOLDSMITH MARK A director, officer..	Common Stock	11,714	$45.4	$531,862
Sale	16 Dec 2024	CISLINI JEFF officer: General Counsel officer: General Counsel	Common Stock	1,599	$45.4	$72,601
Sale	16 Dec 2024	ANDERS JACK officer: Chief Financial Officer officer: Chief Financial Officer	Common Stock	2,635	$45.4	$119,640
Purchase	5 Dec 2024	SCHROEDER THILO director director	Common Stock	543,478	$46	$24,999,988
Purchase	5 Dec 2024	SCHROEDER THILO director director	Common Stock	760,869	$46	$34,999,974
Sale	15 Nov 2024	CISLINI JEFF officer: General Counsel officer: General Counsel	Common Stock	2,554	$55.13	$140,812

RVMD insider trading transactions

Status	Patent	Filling date	Issue date
Application	Application COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF Filling date: 11 Jun 2021 Issue date: 12 May 2022	11 Jun 2021	12 May 2022
Application	Application COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF Filling date: 10 Jun 2021 Issue date: 12 May 2022	10 Jun 2021	12 May 2022
Application	Application BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF Filling date: 2 Mar 2020 Issue date: 5 May 2022	2 Mar 2020	5 May 2022
Application	Application RAS INHIBITORS Filling date: 15 Sep 2021 Issue date: 7 Apr 2022	15 Sep 2021	7 Apr 2022
Application	Application IDENTIFYING NEW THERAPEUTIC AGENTS Filling date: 21 Dec 2020 Issue date: 17 Mar 2022	21 Dec 2020	17 Mar 2022
Application	Application SHP2 INHIBITOR COMPOSITIONS FOR USE IN TREATING CANCER Filling date: 6 Apr 2021 Issue date: 3 Feb 2022	6 Apr 2021	3 Feb 2022
Grant	Grant Utility: Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3S,4S)-4-amino-3-methyl-2- -oxa-8- azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl} methanol, a SHP2 inhibitor Filling date: 26 Feb 2021 Issue date: 11 Jan 2022	26 Feb 2021	11 Jan 2022
Application	Application METHODS AND REAGENTS FOR ANALYZING PROTEIN-PROTEIN INTERFACES Filling date: 28 Jan 2021 Issue date: 30 Dec 2021	28 Jan 2021	30 Dec 2021
Grant	Grant Utility: Bicyclic heteroaryl compounds and uses thereof Filling date: 23 Dec 2020 Issue date: 9 Nov 2021	23 Dec 2020	9 Nov 2021
Application	Application C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors Filling date: 28 Oct 2020 Issue date: 4 Nov 2021	28 Oct 2020	4 Nov 2021

Revolution Medicines
Earnings Call Transcripts

Quarter	Transcript
Q1 2024 8 May 2024	Q1 2024 Earnings Call Transcript
Q4 2023 26 Feb 2024	Q4 2023 Earnings Call Transcript
Q3 2023 6 Nov 2023	Q3 2023 Earnings Call Transcript
Q2 2023 8 Aug 2023	Q2 2023 Earnings Call Transcript

RVMD earnings call transcripts

Revolution Medicines
Executives

Insider	Age	Compensation
Dr. Mark A. Goldsmith Ph.D. (1962) Chief Executive Officer, Pres & Chairman	63	$962,010
Dr. Stephen M. Kelsey M.D., FRCP, FRC Path. (1961) Pres of R&D	64	$739,910
Ms. Margaret A. Horn (1963) Chief Operating Officer, Gen. Counsel & Sec.	62	$735,390

Revolution Medicines
Latest News

Sunday, 15 December 2024
08:20	Insiders Are Loving These 6 Stocks Right Now	247wallst.com
Thursday, 5 December 2024
16:05	Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares	globenewswire.com
Wednesday, 4 December 2024
09:09	Revolution Medicines: Risky Buy On Recent Share Price Dip	seekingalpha.com
Tuesday, 3 December 2024
22:38	Revolution Medicines Announces Pricing of Upsized $750.0 Million Public Offering of Common Stock and Pre-Funded Warrants	globenewswire.com
Monday, 2 December 2024
16:31	Revolution Medicines Announces Commencement of Public Offering of Common Stock	globenewswire.com
07:30	Revolution Medicines Provides Clinical Updates from its RAS(ON) Inhibitor Portfolio	globenewswire.com
Wednesday, 27 November 2024
16:05	Revolution Medicines to Host RAS(ON) Inhibitor Clinical Update Webcast on December 2, 2024	globenewswire.com
Wednesday, 6 November 2024
19:52	Revolution Medicines, Inc. (RVMD) Q3 2024 Earnings Call Transcript	seekingalpha.com
16:02	Revolution Medicines Reports Third Quarter 2024 Financial Results and Update on Corporate Progress	globenewswire.com
Tuesday, 5 November 2024
09:00	Revolution Medicines to Participate in Upcoming Investor Conferences	globenewswire.com
Wednesday, 30 October 2024
16:05	Revolution Medicines to Report Financial Results for Third Quarter 2024 After Market Close on November 6, 2024	globenewswire.com
Friday, 25 October 2024
04:15	Revolution Medicines Presents Initial Data from RMC-9805 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma	globenewswire.com
Wednesday, 23 October 2024
06:00	Revolution Medicines Presents Updated Data from RMC-6236 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma	globenewswire.com
Monday, 21 October 2024
16:05	Revolution Medicines Announces First Patient Dosed in Phase 3 Study Evaluating RMC-6236 in Previously Treated Patients with Metastatic Pancreatic Ductal Adenocarcinoma	globenewswire.com
Monday, 7 October 2024
09:00	Revolution Medicines to Deliver Multiple Presentations at the 2024 AACR-NCI-EORTC Symposium and Host Investor Webcast	globenewswire.com
Sunday, 11 August 2024
02:00	Revolution Medicines, Inc. (RVMD) Q2 2024 Earnings Call Transcript	seekingalpha.com
Wednesday, 7 August 2024
16:05	Revolution Medicines Reports Second Quarter 2024 Financial Results and Update on Corporate Progress	globenewswire.com
Wednesday, 31 July 2024
16:05	Revolution Medicines to Report Financial Results for Second Quarter 2024 After Market Close on August 7, 2024	globenewswire.com
Tuesday, 16 July 2024
08:16	Top 3 Health Care Stocks That Should Keep You Up At Night This Quarter	benzinga.com
Thursday, 11 July 2024
12:00	Revolution Medicines Announces Publication Demonstrating Robust Anti-Tumor Activity of RAS(ON) Inhibitors in Preclinical Models of Refractory KRAS-Mutated Non-Small Cell Lung Cancer	globenewswire.com
Wednesday, 10 July 2024
07:01	Revolution Medicines (RVMD) Moves 11.0% Higher: Will This Strength Last?	zacks.com
Monday, 8 July 2024
16:05	Revolution Medicines to Provide Update on RMC-6236 Pancreatic Ductal Adenocarcinoma Clinical Program on July 15, 2024	globenewswire.com
09:00	SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Revolution Medicines, Inc. (NASDAQ: RVMD)	prnewswire.com
Saturday, 8 June 2024
09:00	The 7 Most Undervalued Under-$50 Stocks to Buy in June 2024	investorplace.com
Wednesday, 5 June 2024
16:05	Revolution Medicines to Participate in Goldman Sachs 45th Annual Global Healthcare Conference	globenewswire.com
Wednesday, 8 May 2024
16:02	Revolution Medicines Reports First Quarter 2024 Financial Results and Update on Corporate Progress	globenewswire.com
Wednesday, 1 May 2024
16:05	Revolution Medicines to Report Financial Results for First Quarter 2024 After Market Close on May 8, 2024	GlobeNewsWire
Thursday, 4 April 2024
16:05	Revolution Medicines to Participate in Upcoming Investor Conferences	GlobeNewsWire
Monday, 26 February 2024
18:21	Revolution Medicines, Inc. (RVMD) Reports Q4 Loss, Lags Revenue Estimates	Zacks Investment Research
Tuesday, 20 February 2024
16:05	Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2023 After Market Close on February 26, 2024	GlobeNewsWire

Ideas & Opinions

Seeking Alpha 19 Jun 2025

Revolution Medicines: Positioning Itself To Capture One Of The Largest Cancer Targets In History
Seeking Alpha 9 Jul 2024

Biotech Stocks 2024 Second Half Outlook - Buy Biotechs
Seeking Alpha 25 Sep 2023

Revolution Medicines: A Big Pipeline In Need Of Big Data
Seeking Alpha 25 Sep 2023

Revolution Medicines' Strategic Edge In RAS-Driven Oncology
Seeking Alpha 11 Jul 2023

Revolution Medicines: Early-Stage Firm Whose High Valuation I Cannot Explain
Seeking Alpha 7 Dec 2022

Revolution Medicines: Highly Differentiated Offering Gaining Traction

Frequently Asked Questions (FAQ)

What's the price of Revolution Medicines stock today?

One share of Revolution Medicines stock can currently be purchased for approximately $36.54.
When is Revolution Medicines's next earnings date?

Unfortunately, Revolution Medicines's (RVMD) next earnings date is currently unknown.
Does Revolution Medicines pay dividends?

No, Revolution Medicines does not pay dividends.
How much money does Revolution Medicines make?

Revolution Medicines has a market capitalization of 7.91B and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 67.27% to 11.58M US dollars.
What is Revolution Medicines's stock symbol?

Revolution Medicines, Inc. is traded on the NASDAQ under the ticker symbol "RVMD".
What is Revolution Medicines's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Revolution Medicines?

Shares of Revolution Medicines can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Revolution Medicines's key executives?
Revolution Medicines's management team includes the following people:
- Dr. Mark A. Goldsmith Ph.D. Chief Executive Officer, Pres & Chairman(age: 63, pay: $962,010)
- Dr. Stephen M. Kelsey M.D., FRCP, FRC Path. Pres of R&D(age: 64, pay: $739,910)
- Ms. Margaret A. Horn Chief Operating Officer, Gen. Counsel & Sec.(age: 62, pay: $735,390)
How many employees does Revolution Medicines have?

As Jul 2024, Revolution Medicines employs 411 workers, which is 9% more then previous quarter.
When Revolution Medicines went public?

Revolution Medicines, Inc. is publicly traded company for more then 5 years since IPO on 13 Feb 2020.
What is Revolution Medicines's official website?

The official website for Revolution Medicines is revmed.com.
Where are Revolution Medicines's headquarters?

Revolution Medicines is headquartered at 700 Saginaw Drive, Redwood City, CA.
How can i contact Revolution Medicines?

Revolution Medicines's mailing address is 700 Saginaw Drive, Redwood City, CA and company can be reached via phone at +65 04816801.
What is Revolution Medicines stock forecast & price target?

Based on 5 Wall Street analysts` predicted price targets for Revolution Medicines in the last 12 months, the avarage price target is $63.86. The average price target represents a 74.75% change from the last price of $36.54.

Revolution Medicines, Inc.

revmed.com

Exchange:

NASDAQ

Full time employees:

490

Industry:

Biotechnology

Sector:

Healthcare

Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

+65 04816801

700 Saginaw Drive
Redwood City, CA 94063

CIK: 0001628171
ISIN: US76155X1000
CUSIP: 76155X100